Non-interventional study
LOOK-UP: Active pharmacovigilance study of the medicine Rinvoq™ (upadacitinib)
Portugal
EU PAS number:
EUPAS1000000227
First published:
14/03/2025
StudyFinalised
Shortening the time to confirm or to rebut Adverse events of interest related to innovative Therapies for immune-mediated inflammATory dIseases: cross-talking between different data sOURces. SATURATIOn study.
France
EU PAS number:
EUPAS1000000207
First published:
27/06/2024
StudyPlanned
A Non-Interventional Multi-Database Post-Authorisation Study to Assess Pregnancy-Related Safety Data from Women with Severe Asthma Exposed to Tezepelumab (TREATY)
Denmark
France
Sweden
United States
EU PAS number:
EUPAS1000000176
First published:
17/12/2024
StudyPlanned
An Observational Multi-Country Post-Authorisation Safety Study to Evaluate the Risk of Serious Adverse Cardiovascular Events in Adolescent and Adult Patients with Severe Asthma taking Tezepelumab (TRESPASS)
Denmark
France
Germany
United States
EU PAS number:
EUPAS1000000169
First published:
24/05/2024
StudyPlanned
A registry-based non-interventional post-authorization safety study to evaluate the long-term safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis using the PEDISTAD registry: a cohort design
Argentina
Australia
Belgium
Brazil
Canada
China
Colombia
Denmark
France
Greece
Israel
Italy
Japan
Korea, Republic of
Mexico
Netherlands
Norway
Portugal
Russian Federation
Spain
United States
EU PAS number:
EUPAS1000000149
First published:
10/03/2025
StudyOngoing
An observational, Post-Authorisation Safety Study (PASS) to describe the safety and effectiveness of tabelecleucel in patients with Epstein-Barr Virus positive (EBV+) Post-Transplant Lymphoproliferative Disease (PTLD) in a real-world setting in Europe: EBVOLVE study
European Union
EU PAS number:
EUPAS1000000113
First published:
12/11/2024
StudyPlanned
Real world management of pain: Do patient-specific factors influence treatment decisions and its outcomes? (RELIEF)
Bosnia and Herzegovina
Croatia
Czechia
North Macedonia
Serbia
EU PAS number:
EUPAS1000000079
First published:
25/03/2024
StudyFinalised
CROSSROADS-1: Treatment Outcomes among Tezspire Users: A Claims Data Study (20230159)
United States
EU PAS number:
EUPAS1000000062
First published:
09/12/2024
StudyOngoing
CROSSROADS-2: Clinical Characteristics, Treatment Patterns, and Treatment Outcomes Among Users of Tezspire: An Electronic Medical Record (EMR) study (20220066)
United States
EU PAS number:
EUPAS1000000053
First published:
13/11/2024
StudyOngoing
Post Marketing Surveillance of Effectiveness (All-Cause Mortality) of Posaconazole Injection and Tablet Treatment of Invasive Aspergillosis in Chinese patients (MK-5592-141)
China
EU PAS number:
EUPAS108481
First published:
14/02/2025
StudyOngoing